Steve Scala
Stock Analyst
(n/a)
# 4,652
Out of 4,654 analysts
31
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steve Scala
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Buy | $195 → $225 | $164.99 | +36.37% | 12 | Oct 7, 2024 | |
| BMY Bristol-Myers Squibb Company | Maintains: Hold | $53 → $59 | $56.22 | +4.94% | 3 | Oct 7, 2024 | |
| AZN AstraZeneca | Maintains: Buy | $90 → $95 | $63.23 | +50.25% | 1 | Aug 12, 2024 | |
| MRK Merck & Co. | Upgrades: Outperform | $125 → $135 | $96.31 | +40.17% | 1 | Jan 4, 2024 | |
| PFE Pfizer | Downgrades: Market Perform | $32 | $24.80 | +29.03% | 1 | Jan 4, 2024 | |
| LLY Eli Lilly | Maintains: Outperform | $430 → $500 | $746.20 | -32.99% | 8 | May 23, 2023 | |
| NVS Novartis AG | Downgrades: Market Perform | $110 → $105 | $103.06 | +1.88% | 4 | Feb 1, 2021 | |
| RPRX Royalty Pharma | Initiates: Outperform | $55 | $25.70 | +114.01% | 1 | Jul 13, 2020 |
AbbVie
Oct 7, 2024
Maintains: Buy
Price Target: $195 → $225
Current: $164.99
Upside: +36.37%
Bristol-Myers Squibb Company
Oct 7, 2024
Maintains: Hold
Price Target: $53 → $59
Current: $56.22
Upside: +4.94%
AstraZeneca
Aug 12, 2024
Maintains: Buy
Price Target: $90 → $95
Current: $63.23
Upside: +50.25%
Merck & Co.
Jan 4, 2024
Upgrades: Outperform
Price Target: $125 → $135
Current: $96.31
Upside: +40.17%
Pfizer
Jan 4, 2024
Downgrades: Market Perform
Price Target: $32
Current: $24.80
Upside: +29.03%
Eli Lilly
May 23, 2023
Maintains: Outperform
Price Target: $430 → $500
Current: $746.20
Upside: -32.99%
Novartis AG
Feb 1, 2021
Downgrades: Market Perform
Price Target: $110 → $105
Current: $103.06
Upside: +1.88%
Royalty Pharma
Jul 13, 2020
Initiates: Outperform
Price Target: $55
Current: $25.70
Upside: +114.01%